rs67006588
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_172245.4(CSF2RA):āc.50C>Gā(p.Ala17Gly) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0664 in 1,613,236 control chromosomes in the GnomAD database, including 15,059 homozygotes. There are 50,831 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. 12/17 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (ā ā ).
Frequency
Consequence
NM_172245.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CSF2RA | NM_172245.4 | c.50C>G | p.Ala17Gly | missense_variant | 3/13 | ENST00000381529.9 | NP_758448.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CSF2RA | ENST00000381529.9 | c.50C>G | p.Ala17Gly | missense_variant | 3/13 | 1 | NM_172245.4 | ENSP00000370940.3 |
Frequencies
GnomAD3 genomes AF: 0.194 AC: 29461AN: 151968Hom.: 7334 Cov.: 31 AF XY: 0.187 AC XY: 13853AN XY: 74228
GnomAD3 exomes AF: 0.0782 AC: 19629AN: 251158Hom.: 3180 AF XY: 0.0669 AC XY: 9075AN XY: 135728
GnomAD4 exome AF: 0.0531 AC: 77589AN: 1461150Hom.: 7707 Cov.: 31 AF XY: 0.0508 AC XY: 36934AN XY: 726888
GnomAD4 genome AF: 0.194 AC: 29513AN: 152086Hom.: 7352 Cov.: 31 AF XY: 0.187 AC XY: 13897AN XY: 74356
ClinVar
Submissions by phenotype
not provided Benign:2
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Jan 13, 2019 | - - |
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Feb 21, 2013 | Ala17Gly in exon 4 of CSF2RA: This variant is not expected to have clinical sign ificance because it has been identified in 42.5% (1874/4406) of African American chromosomes from a broad population by the NHLBI Exome Sequencing Project (http ://evs.gs.washington.edu/EVS; dbSNP rs142270234). - |
Surfactant metabolism dysfunction, pulmonary, 4 Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
CSF2RA-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 21, 2019 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at